The Patent Finder

Terms ending in 2041

Ablynx N.V.

Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,840,566Methods of Treating Asthma with Polypeptides Targeting IL-13 and TSLP
In force
 · Medium confidence
N.V., AblynxIn forceMedium confidence
US 11,897,951POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF-a
In force
 · High confidence
Ablynx N.V.In forceHigh confidence
US 11,932,702Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting GLYPICAN-3 and T Cell Receptor
In force
 · High confidence
Ablynx N.V.In forceHigh confidence
US 12,709,646Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting GLYPICAN-3 and T Cell Receptor
In force
 · Medium confidence
Ablynx N.V.In forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Ablynx N.V..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited